Originally published October 18 2004
Arthritis drug Celebrex to go through clinical trial after Vioxx problems
by Mike Adams, the Health Ranger, NaturalNews Editor
The question, though, is will Pfizer tell the truth about the results of this clinical trial? What happens if Celebrex is also found to exhibit dangerous side effects that enhance the risk of cardiovascular disease?
-
Pfizer Inc. said Monday it is planning a clinical study to evaluate how effective its pain medication Celebrex is in treating patients with cardiovascular problems.
- Pfizer (PFE: news, chart, profile) shares were trading up almost 1 percent at $28.78 during a generally positive session for the pharmaceutical sector on Wall Street.
- The study will be an extension of a larger study designed to measure Celebrex's effects on the cardiovascular system.
- The new study, which will include about 4,000 participants, will begin in early 2005, according to Pfizer.
- Earlier this month, Merck & Co. (MRK: news, chart, profile) pulled its arthritis pain drug Vioxx from the market after a clinical study showed that patients who took the drug for more than 18 months exhibited a notably higher incidence rate of heart attack and stroke.
All content posted on this site is commentary or opinion and is protected under Free Speech. Truth Publishing LLC takes sole responsibility for all content. Truth Publishing sells no hard products and earns no money from the recommendation of products. NaturalNews.com is presented for educational and commentary purposes only and should not be construed as professional advice from any licensed practitioner. Truth Publishing assumes no responsibility for the use or misuse of this material. For the full terms of usage of this material, visit www.NaturalNews.com/terms.shtml